OPRD1
ENSG00000116329
Target class
GPCR
Chromosome
1
Approved drugs
14
Clinical candidates (approved and in development)
21
- Approved drugs
- 14
- Clinical candidates (approved and in development)
- 21
- Chemical probe available
- Yes
- Target name
- OPRD1
- Gene name
- Opioid receptor delta 1
- Gene symbol
- OPRD1
- Protein name
- Delta-type opioid receptor (D-OR-1) (DOR-1)
- Gene biotype
- Protein coding
- Gene family
- Opioid receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 6
- Highest tissue expression
- 3.49
- Tissue specificity (Gini)
- 0.752
- Tissue specificity (tau)
- 0.927
- KEGG gene identifiers
- hsa:4985
- Protein interaction confidence
- 0.8812
- Protein interaction partners
- 15
- R-HSA-375276
- R-HSA-418594
- R-HSA-6785807
- End position
- 28871267
- Start position
- 28812170
- Chromosome
- 1
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 22184124
- PubMed 7808419
- PubMed 8201839
- Tissue specificity (tau)
- 0.92734
- Expression inequality (Gini)
- 0.75239
Expression in transcripts per million
- Brain - Cortex
- 3.49
- Brain - Frontal Cortex (BA9)
- 3.27
- Brain - Anterior cingulate cortex (BA24)
- 1.46
- Brain - Putamen (basal ganglia)
- 1.32
- Brain - Caudate (basal ganglia)
- 1.23
Expression in transcripts per million
- Brain - Cortex3.49
- Brain - Frontal Cortex (BA9)3.27
- Brain - Anterior cingulate cortex (BA24)1.46
- Brain - Putamen (basal ganglia)1.32
- Brain - Caudate (basal ganglia)1.23
- Brain - Nucleus accumbens (basal ganglia)1.08
- Brain - Amygdala0.66
- Brain - Hippocampus0.56
- Brain - Hypothalamus0.45
- Colon - Sigmoid0.38
- Testis0.34
- Small Intestine - Terminal Ileum0.19
- Pituitary0.18
- Spleen0.15
- Colon - Transverse0.12
- Lung0.1
- Brain - Substantia nigra0.1
- Brain - Cerebellum0.1
- Stomach0.1
- Brain - Spinal cord (cervical c-1)0.09
- Brain - Cerebellar Hemisphere0.09
- Pancreas0.09
- Prostate0.08
- Thyroid0.08
- Adipose - Visceral (Omentum)0.07
And 29 more, listed on the interactive page.
- GO:0006955
- GO:0007186
- GO:0007187
- GO:0010629
- GO:0031333
- GO:0038003
- GO:0051881
- GO:0071456
- GO:0097237
Cellular components
- GO:0005886
- GO:0004985
- GO:0005515
- GO:0038046
seizure
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: seizure
- cardiovascular system
- nervous system
Evidence sourceincreased cardiac output
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: increased cardiac output
- cardiovascular system
- nervous system
Evidence sourceeuphoria
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: euphoria
Biological samples
- central nervous system
PubMed 28216264increased contractility
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: increased contractility
- cardiovascular system
- nervous system
Evidence sourceincreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: increased blood pressure
- cardiovascular system
- nervous system
Evidence sourceconvulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: convulsions
Biological samples
- central nervous system
PubMed 28216264convulsion
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: convulsion
- cardiovascular system
- nervous system
Evidence sourcerespiratory depression
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: respiratory depression
Biological samples
- central nervous system
PubMed 28216264increased bloodflow to the heart
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: increased bloodflow to the heart
- cardiovascular system
- nervous system
Evidence sourceincreased bloodflow to the skeletal muscle
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: increased bloodflow to the skeletal muscle
- cardiovascular system
- nervous system
Evidence sourcerespiratory depression
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: respiratory depression
- cardiovascular system
- nervous system
Evidence sourcedecreased gastrointestinal transit
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased gastrointestinal transit
Biological samples
- central nervous system
PubMed 28216264increased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased locomotor activity
Biological samples
- central nervous system
PubMed 28216264dysphoria
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: dysphoria
- cardiovascular system
- nervous system
Evidence sourceincreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased pain
Biological samples
- central nervous system
PubMed 28216264increased bloodflow to the kidneys
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: increased bloodflow to the kidneys
- cardiovascular system
- nervous system
Evidence sourceanalgesia
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: analgesia
- cardiovascular system
- nervous system
Evidence sourcedecreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
Biological samples
- central nervous system
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
Biological samples
- central nervous system
PubMed 28216264heart effects
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: heart effects
- cardiovascular system
- nervous system
Evidence sourceincreased bloodflow to the gastrointestinal tract
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: increased bloodflow to the gastrointestinal tract
- cardiovascular system
- nervous system
Evidence sourcecardiovascular effects
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: cardiovascular effects
- cardiovascular system
- nervous system
Evidence sourcepsychomimetic effects
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: psychomimetic effects
- cardiovascular system
- nervous system
Evidence sourceincreased anxiety
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased anxiety
Biological samples
- central nervous system
PubMed 28216264
dysphoria
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: dysphoria
- cardiovascular system
- central nervous system
PubMed 23197038increased cardiac contractility
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased cardiac contractility
- cardiovascular system
- central nervous system
PubMed 23197038psychomimetic effects
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: psychomimetic effects
- cardiovascular system
- central nervous system
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hOpiate_D1, is one of one assay component(s) measured or calculated from the NVS_GPCR_hOpiate_D1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourcecardiovascular effects
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: cardiovascular effects
- cardiovascular system
- central nervous system
PubMed 23197038convulsion
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: convulsion
- cardiovascular system
- central nervous system
PubMed 23197038increased blood pressure
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased blood pressure
- cardiovascular system
- central nervous system
PubMed 23197038analgesia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: analgesia
- cardiovascular system
- central nervous system
PubMed 23197038
Related records
Trials (1,097)
- [11C]Carfentanil PET Study of GSK1521498
- 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
- 5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial
- A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)
- A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.
- A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure to Investigate the Safety and Tolerability of GRT0151Y and to Find Out Which Single Dose of the Compound is Maximally Tolerated
- A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused
- A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body
- A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS
- A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol
- A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use
- A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.
- A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
- A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy
- A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery
- A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
- A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.
- A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
- A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder
- A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)
Drugs (30)
- ADL-5747 Delta opioid receptor agonist
- ADL-5747 FREE BASE Delta opioid receptor agonist
- ADL-5859 Delta opioid receptor agonist
- Axomadol Delta opioid receptor agonist
- AZD-7268 Delta opioid receptor agonist
- Benzhydrocodone Opioid receptors; mu/kappa/delta agonist
- Benzhydrocodone hydrochloride Opioid receptors; mu/kappa/delta agonist
- Cebranopadol Opioid receptors; mu/kappa/delta agonist
- Codeine Opioid receptors; mu/kappa/delta agonist
- Codeine phosphate Opioid receptors; mu/kappa/delta agonist
- Codeine polistirex Opioid receptors; mu/kappa/delta agonist
- Codeine sulfate Opioid receptors; mu/kappa/delta agonist
- Dextromoramide Opioid receptors; mu/kappa/delta agonist
- Hydrocodone Opioid receptors; mu/kappa/delta agonist
- Hydrocodone bitartrate Opioid receptors; mu/kappa/delta agonist
- Hydrocodone polistirex Opioid receptors; mu/kappa/delta agonist
- Nalbuphine Opioid receptors; mu/kappa/delta agonist
- Nalbuphine hydrochloride Opioid receptors; mu/kappa/delta agonist
- Nalmefene Delta opioid receptor antagonist
- Nalmefene hydrochloride dihydrate Delta opioid receptor antagonist